Information Provided By:
Fly News Breaks for January 10, 2020
Jan 10, 2020 | 06:01 EDT
Nomura Instinet analyst Christopher Marai initiated coverage of Kadmon with a Buy rating and $10 price target. The analyst believes the company's success in indications beyond chronic graft versus host disease expected in 2020 will pave the way for a broader, and multi-blockbuster, opportunity for ROCK inhibition across autoimmune and fibrotic diseases.
News For KDMN From the Last 2 Days
There are no results for your query KDMN